As for erythropoietic-stimulating agent therapy, it was suitable only forpatients receiving palliative, myelosuppressive chemotherapy with a Hb <10 g/dLand without absolute iron deficiency [39]. Here, GSTM1 is linked to Iron deficiency anemia.